Lung deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiency

European Respiratory Journal

Volumn 34, Issue 2, 2008, Pages 354-360

  Brand, P ^a   Schulte, M ^a   Wencker, M ^b   Herpich, C H ^a   Klein, G ^c   Hanna, K ^c   Meyer, T ^a  

^a Inamed Research GmbH and Co KG   (Germany)

^b Talecris Biotherapeutics GmbH   (Germany)

^c Talecris Biotherapeutics Inc   (United States)

Author keywords

1 antitrypsin; 1 antitrypsin deficiency; Controlled inhalation; Cystic fibrosis; Deposition; Nebuliser

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BREATHING PATTERN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DEVICE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DEPOSITION; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; HEADACHE; HUMAN; ISOTOPE LABELING; LUNG FUNCTION TEST; MALE; NEBULIZER; PRIORITY JOURNAL; REPRODUCIBILITY; TONGUE DISEASE; TONGUE VESICLE;

ADOLESCENT; ADULT; AEROSOLS; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LUNG; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 69249120315     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00118408     Document Type: Article

References (18)

1. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 2003; 64: 382-397.
2. 1-antitrypsin deficiency in European countries. Eur Respir J 2006; 27: 77-84.
3. 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001; 22: 165-171.
4. Birrer P, McElvaney NG, Rüdeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
5. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
6. 1-antitrypsin gene and its mutations. Chest 1989; 95: 196-208.
7. 1-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulm Pharmacol Ther 2001; 14: 461-467.
8. 1-antitrypsin. Ann Intern Med 1989; 111: 206-212.
9. Brand P, Meyer T, Häussermann S, et al. Optimum peripheral drug deposition in patientswith cystic fibrosis. J Aerosol Med 2005; 18: 45-54.
10. 1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22: 263-267.
11. Scheuch G, Meyer T, Mullinger B, et al. Controlled inhalation improves peripheral lung deposition. J Aerosol Sci 2001; 14: 388.
12. 1 antitrypsin in aerosol therapy. Nucl Med Biol 1998; 25: 509-513.
13. Bennett WD, Brown JS, Zeman KL, et al. Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002; 15: 179-188.
14. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997; 10: 187-198.
15. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests European Community for Steel and Coal. Eur Respir J 1993; 6: Suppl. 16, 5-40.
16. Brand P, Friemel I, Meyer T, et al. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000; 89: 724-731.
17. 1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155: 536-541.
18. 1- antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-250.